VIALE-A长期随访:维奈克拉联合阿扎胞苷治疗不适合化疗的初诊急性髓系白血病
VIALE-A研究最终分析在预设360例总生存事件全部发生时进行,中位随访43.2个月,维奈克拉联合阿扎胞苷组中位总生存14.7个月,安慰剂联合阿扎胞苷组9.6个月(HR 0.58,95%CI 0.47-0.72,p<.001),长期疗效与安全性支持该方案作为不适合强化化疗AML患者的标准治疗改进。
要点
- 维奈克拉联合阿扎胞苷组中位总生存14.7个月,对照组9.6个月,HR 0.58。
- 24个月总生存率分别为37.5%与16.9%。
- 未发现新的安全性信号。
核心结论
- 长期疗效和安全性证实维奈克拉联合阿扎胞苷是不适合强化化疗的急性髓系白血病患者标准治疗的改进。
研究设计与样本
- VIALE-A研究(NCT02993523)为随机对照研究,患者按2:1随机接受维奈克拉联合阿扎胞苷或安慰剂联合阿扎胞苷。
- 共纳入431例不适合强化化疗的初诊急性髓系白血病患者,维奈克拉联合阿扎胞苷组286例,安慰剂联合阿扎胞苷组145例。
- 最终分析在预设的360例总生存事件全部发生时进行,中位随访43.2个月。
主要发现
- 中位总生存:维奈克拉联合阿扎胞苷组14.7个月(95%CI 12.1-18.7)vs 安慰剂联合阿扎胞苷组9.6个月(95%CI 7.4-12.7),HR 0.58(95%CI 0.47-0.72),p<.001。
- 估计24个月总生存率:维奈克拉联合阿扎胞苷组37.5% vs 安慰剂联合阿扎胞苷组16.9%。
- 伴IDH1/2突变患者及达到可测量残留病应答患者的中位总生存在此次最终分析时达到。
- 完全缓解伴或不伴血细胞计数恢复(CR/CRi)率与中期分析相似。
- 任何级别血液学及胃肠道不良事件在两组均最常见,包括血小板减少(维奈克拉联合阿扎胞苷组47% vs 安慰剂联合阿扎胞苷组42%)和中性粒细胞减少(43% vs 29%)。
关键数值与推荐
- 主要终点为总生存。
- 关键次要终点为完全缓解伴或不伴血细胞计数恢复(CR/CRi)。
临床怎么用
- 维奈克拉联合阿扎胞苷适用于因高龄或合并症不适合强化化疗的初诊急性髓系白血病患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax-azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE-A study (NCT02993523). Here, long-term follow-up is presented to address survival benefit and long-term outcomes with venetoclax-azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax-azacitidine or placebo-azacitidine. OS was the primary endpoint; complete remission with/without blood count recovery (CR/CRi) was a key secondary endpoint. This final analysis was conducted when 100% of the predefined 360 OS events occurred. In VIALE-A, 431 patients were enrolled to venetoclax-azacitidine (n = 286) or placebo-azacitidine (n = 145). At 43.2 months median follow-up, median OS was 14.7 months (95% confidence interval [CI], 12.1-18.7) with venetoclax-azacitidine, and 9.6 months (95% CI, 7.4-12.7) with placebo-azacitidine (hazard ratio, 0.58 [95% CI, 0.47-0.72], p < .001); the estimated 24-month OS rate was 37.5% and 16.9%, respectively. Median OS for patients with IDH1/2 mutations and those with measurable residual disease responses was reached in this final analysis. CR/CRi rate was similar to interim analysis. Any-grade hematologic and gastrointestinal adverse events were most common in venetoclax-azacitidine and placebo-azacitidine arms, including thrombocytopenia (47% and 42%) and neutropenia (43% and 29%). No new safety signals were identified. Long-term efficacy and safety confirm venetoclax-azacitidine is an improvement in standard-of-care for patients with AML who are not eligible for intensive chemotherapy because of advanced age or comorbidities.
引用
- Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024. PMID: 38343151. doi:10.1002/ajh.27246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。